SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report: July 18, 2002
(Date of earliest event reported)
DELTAGEN, INC.
(Exact name of Registrant as specified in its Charter)
Delaware | | 000-31147 | | 94-3260659 |
(State or other jurisdiction of incorporation or organization) | | (Commission File No.) | | (IRS Employer Identification No.) |
740 Bay RoadRedwood City, CA | | 94063 |
(Address of principal executive offices) | | (Zip Code) |
(650) 569-5100
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report.)
Item 5. Other Events.
On July 18, 2002, Deltagen, Inc. (“Deltagen”) announced the discovery of a drug target for the potential treatment of rheumatoid arthritis. Further details regarding this announcement are contained in Deltagen’s news release dated July 18, 2002 attached as an exhibit hereto and incorporated herein by reference.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(a) Not applicable
(b) Not applicable
(c) See attached Exhibits Index.
EXHIBIT INDEX
Number
| | Exhibit
|
|
| 99.1 | | Deltagen, Inc. News Release dated July 18, 2002. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
DELTAGEN, INC. |
|
| By: | | /s/ JOHN E. BURKE
|
| | | John E. Burke Senior Vice President of Intellectual Property and General Counsel |
Date: July 18, 2002
